The approval marks the first small interfering RNA therapy for low-density lipoprotein cholesterol reduction. Inclisiran (Leqvio; Novartis) has become the first small interfering RNA (siRNA) therapy to be approved by…
The approval marks the first small interfering RNA therapy for low-density lipoprotein cholesterol reduction. Inclisiran (Leqvio; Novartis) has become the first small interfering RNA (siRNA) therapy to be approved by…